Rabinowitz Matthew sold $20.1M of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 50,000 shares of Natera, Inc. (NTRA) at an average of $402.64 ($388.32–$408.24, $20.13M total) across 19 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Oct 17, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
high confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishMed
01

Why it matters

The disclosed $20M sale adds supply to the market and could trigger short‑term price decline, especially given the executive's high‑profile role.

02

Market read

First‑report insider sale of significant size; likely short‑term bearish catalyst for NTRA.

03

What to watch

Potential upcoming clinical data releases or partnership announcements could offset sell pressure.

Relevance 6/10Novelty 8/10Timing: post‑market 2026‑10‑15

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NTRABearishHigh confidence
Context

Executive Chairman Rabinowitz sold 50,000 NTRA shares for $20.1M via a 10b5‑1 plan on 2026‑10‑15.

Expected impact

downward pressure as the market prices in the insider sell.

Evidence & confidence

The sale represents a $20M disposition by a top officer, likely prompting short‑term selling.

Market effects

May weigh on other prenatal‑testing and diagnostics firms as insider selling raises sector risk perception.

Limited to U.S. biotech market; no broader regional effect.

Minimal global impact beyond Natera shareholders.

Counterpoint

The sale follows a pre‑arranged 10b5‑1 plan and may not reflect personal sentiment; price could remain stable.

Key entities

  • Rabinowitz Matthew

    Executive Chairman of Natera, Inc.

  • Natera, Inc.

    NASDAQ‑listed prenatal‑testing and diagnostics company.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.